Published in Clin Exp Immunol on September 01, 2010
Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci (2012) 1.63
α-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls. PLoS One (2012) 0.87
Intravenous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation (2013) 0.83
Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease. J Neuroinflammation (2012) 0.80
Novel therapeutic approaches in multiple system atrophy. Clin Auton Res (2014) 0.76
Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins. J Cent Nerv Syst Dis (2011) 0.75
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
A QUANTITATIVE THEORY OF THE PRECIPITIN REACTION : III. THE REACTION BETWEEN CRYSTALLINE EGG ALBUMIN AND ITS HOMOLOGOUS ANTIBODY. J Exp Med (1935) 13.36
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A (1998) 8.41
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (2004) 7.69
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron (1995) 4.78
A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem (2000) 3.97
Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1993) 3.73
Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J (2005) 3.60
Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron (2005) 3.20
Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J (2003) 2.64
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging (2008) 2.24
Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett (1998) 2.14
Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2004) 2.12
Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res (1999) 1.93
Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem (2002) 1.77
Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci (2007) 1.75
Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Int Immunopharmacol (2009) 1.65
Genetics of Parkinson's disease. Curr Opin Neurol (2005) 1.59
Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. J Mol Neurosci (2007) 1.51
"Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. Ann N Y Acad Sci (2000) 1.31
Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem (2001) 1.29
Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am J Pathol (1996) 1.23
Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem (2007) 1.22
Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J (2006) 1.17
alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett (2004) 1.14
Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol (1999) 1.14
Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry (2004) 1.12
A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J (2004) 1.07
Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores. Neurosci Lett (1999) 1.03
Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations. J Allergy Clin Immunol (2008) 1.01
Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci (2007) 1.00
Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. Exp Brain Res (2006) 0.98
In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations--a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med (2002) 0.93
Measurement of anti-Abeta1-42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding. J Neurosci Methods (2010) 0.89
Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia. Intern Med (2009) 0.88
An enzyme immunoassay to determine the levels of specific antibodies toward bacterial surface antigens in human immunoglobulin preparations and blood serum. J Pharm Biomed Anal (1999) 0.87
Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin. Vox Sang (2008) 0.82
Disease-associated anti-bovine serum albumin antibodies in type 1 (insulin-dependent) diabetes mellitus are detected by particle concentration fluoroimmunoassay, and not by enzyme linked immunoassay. Diabetologia (1992) 0.80
The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies. Curr Med Chem (2008) 0.79
Correlation of immune complexes in disseminated neuroblastoma with serum antibody to bovine serum albumin. Cancer Res (1983) 0.78
Both autoantibodies and pathogen-specific antibodies are present in immunoglobulin preparations and reflect characteristics of the donor population. J Am Acad Dermatol (2008) 0.76
A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem (1995) 1.40
Impact of nonadditive genetic effects in the estimation of breeding values for fertility and correlated traits. J Dairy Sci (2005) 1.13
Differences between primiparous and multiparous dairy cows in the inter-relationships between metabolic traits, milk yield and body condition score in the periparturient period. Domest Anim Endocrinol (2006) 1.11
Multiple correlation analyses of metabolic and endocrine profiles with fertility in primiparous and multiparous cows. J Dairy Sci (2007) 1.04
Inbreeding trends and application of optimized selection in the UK Holstein population. J Dairy Sci (2004) 0.97
Use of enzyme-linked immunosorbent assay to measure bovine milk and serum antibodies to alpha toxin, beta toxin, and capsular antigens of Staphylococcus aureus. Vet Immunol Immunopathol (1987) 0.92
Changes in feeding behavior as possible indicators for the automatic monitoring of health disorders in dairy cows. J Dairy Sci (2008) 0.92
Use of 51Cr release to measure the cytotoxic effects of staphylococcal leukocidin and toxin neutralization on bovine leukocytes. J Clin Microbiol (1986) 0.91
Potential for estimation of body condition scores in dairy cattle from digital images. J Dairy Sci (2008) 0.90
Impact of single nucleotide polymorphisms in leptin, leptin receptor, growth hormone receptor, and diacylglycerol acyltransferase (DGAT1) gene loci on milk production, feed, and body energy traits of UK dairy cows. J Dairy Sci (2008) 0.90
Merging and characterising phenotypic data on conventional and rare traits from dairy cattle experimental resources in three countries. Animal (2012) 0.88
Phenotypic effects of calving ease on the subsequent fertility and milk production of dam and calf in UK Holstein-Friesian heifers. J Dairy Sci (2011) 0.86
Enzyme-linked immunosorbent assay for detection of milk immunoglobulins to leukocidin toxin of Staphylococcus aureus. Am J Vet Res (1985) 0.85
Prenatal maternal effects on body condition score, female fertility, and milk yield of dairy cows. J Dairy Sci (2007) 0.83
Improved accuracy of genomic prediction for dry matter intake of dairy cattle from combined European and Australian data sets. J Dairy Sci (2012) 0.83
Genetic evaluation of fertility using direct and correlated traits. J Dairy Sci (2003) 0.81
L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion. J Neurochem (2000) 0.81
Genetic relationships between calving interval and body condition score conditional on milk yield. J Dairy Sci (2002) 0.80
Genetic relationship between first-lactation body energy and later-life udder health in dairy cattle. J Dairy Sci (2006) 0.79
The effect of genetic merit and production system on dairy cow fertility, measured using progesterone profiles and on-farm recording. J Dairy Sci (2008) 0.79
Short communication: Characterization of the genome-wide linkage disequilibrium in 2 divergent selection lines of dairy cows. J Dairy Sci (2010) 0.78
Genotype by environment interaction for first-lactation female fertility traits in UK dairy cattle. J Dairy Sci (2009) 0.77
The genetic relationship between calving interval, body condition score and linear type and management traits in registered Holsteins. J Dairy Sci (2000) 0.76
The relationship between body condition score and reproductive performance. J Dairy Sci (2001) 0.76
The use of mid-infrared spectrometry to predict body energy status of Holstein cows. J Dairy Sci (2011) 0.76
The relationship between body energy traits and production and fitness traits in first-lactation dairy cows. J Dairy Sci (2007) 0.76
The violent patient. J Adv Nurs (1976) 0.75
Technical note: Prediction of liveweight from linear conformation traits in dairy cattle. J Dairy Sci (2012) 0.75
Genetic profile of total body energy content of Holstein cows in the first three lactations. J Dairy Sci (2005) 0.75
A theoretical framework for deriving direct economic values for body tissue mobilization traits in dairy cattle. J Dairy Sci (2008) 0.75
Genetic parameters of growth in dairy cattle and associations between growth and health traits. J Dairy Sci (2007) 0.75
Modeling daily energy balance of dairy cows in the first three lactations. J Dairy Sci (2005) 0.75
Evaluation of body condition score measured throughout lactation as an indicator of fertility in dairy cattle. J Dairy Sci (2004) 0.75
Genetic association between body energy measured throughout lactation and fertility in dairy cattle. Animal (2010) 0.75
Body trait profiles in Holstein-Friesians modeled using random regression. J Dairy Sci (2005) 0.75
Genetic analysis of carcass traits in beef cattle using random regression models. J Anim Sci (2016) 0.75
Direct and maternal genetic relationships between calving ease, gestation length, milk production, fertility, type, and lifespan of Holstein-Friesian primiparous cows. J Dairy Sci (2013) 0.75
The relationship between fertility, rump angle, and selected type information in Holstein-Friesian cows. J Dairy Sci (2005) 0.75
Transcutaneous bilirubin levels in newborns <35 weeks' gestation. J Perinatol (2015) 0.75
Validation of mid-infrared spectrometry in milk for predicting body energy status in Holstein-Friesian cows. J Dairy Sci (2012) 0.75
The sensitivity of predicted financial and genetic gains in Holsteins to changes in the economic value of traits. J Anim Breed Genet (2012) 0.75